Fairmount Partners Assists Ockham to Fund and Complete a European Acquisition

January 31, 2012

Cary, NC –  Ockham Development Group, Inc. (“Ockham”) announced today its acquisition of Nexus Oncology Ltd (“Nexus”), an Edinburgh, Scotland based CRO focused in oncology. Fairmount Partners served as investment banker and advisor to Ockham. Fairmount introduced Ockham to Spring Capital Partners (“SCP”) and structured the financing which consisted of a $4.5 million mezzanine debt investment from SCP and a senior debt facility. The proceeds from the combined financing are being used to provide corporate working capital and to support the acquisition of Nexus.

James V. Baker, CEO of Ockham said “The acquisition of Nexus is a milestone in the history of Ockham, providing us the ability to sharpen our oncology therapeutic expertise and to significantly expand our global clinical trials management platform. With our existing operations in North America, Europe and India, we can service our clients on global trials. Our financing partnership with SCP will enable us to execute on our aggressive future growth plans.”

David K. Reed, Director at Fairmount added “Ockham is now ideally positioned to offer its drug sponsor clients a complete suite of outsourcing capabilities including clinical research staffing, functional service provider and full service CRO project management. We expect more great things from Ockham and were thrilled to assist in completing the transaction and introducing Ockham to the great team at SCP.”

Michael F. Donoghue, General Partner and co-Founder of SCP remarked “We believe that Jim and his team are poised for significant future growth. We are enthusiastic about the macro trends in the pharmaceutical outsourcing industry and we are excited to be Ockham’s financing partner.”


Ockham is a leading global CRO and FSP organization, supplemented by a robust traditional sourcing component, founded in 1986. The company offers a full range of clinical research services for Phase I-IV clinical trials in oncology, as well as other therapeutic areas. Ockham provides its clients with a combination of medical and technical expertise within their tightly controlled clinical studies. Ockham is headquartered in Cary, North Carolina with satellite offices strategically placed around the United States, India and the United Kingdom to service global customers and operations. For more information about Ockham, visit www.ockham.com.


Founded in 1999, Nexus Oncology offers specialist clinical research services to biopharmaceutical companies developing new cancer treatments. Nexus Oncology has nearly 100 staff across Europe and North America. The company has experience of a wide variety of tumor types and is currently conducting phase I – III oncology clinical trials across Europe, North America and Asia. For more information about Nexus, visit www.nexusoncology.com.


Spring Capital Partners (“SCP) was established in 1999 to provide mezzanine capital to growing small and medium sized businesses. SCP has over $185 million invested or under management and is currently investing out of its second fund. SCP makes investments primarily in the form of subordinated debt with equity features in the range of $2 million to $7 million per investment. While many investments are made to mature companies with institutional equity sponsorship, SCP also makes investments in late stage venture companies. Additionally, SCP makes investments in management-owned companies with strong teams that have proven track records and considerable equity stakes. SCP invests in a broad range of industries with a geographic focus on companies and equity sponsors located in the eastern half of the United States. For more information about SCP, visit www.springcap.com.

Fairmount Partners is a registered Broker Dealer, member FINRA (www.finra.org) and SIPC (www.sipc.org).

Principals of Fairmount Partners acted as advisors to Ockham in this transaction.

Contact: Neal McCarthy or David Reed